Understanding the FDA Pregnancy Drug Classification and Procurement Recommendations: From A/B/C/D/X to PLLR—How Can Pharmacies Optimize Medication Management for Pregnant Patients?
Medication safety during pregnancy has long been a critical concern in global healthcare. For hospitals, pharmacies, pharmaceutical distributors, and healthcare professionals, accurately evaluating the risks of medications during pregnancy and establishing appropriate procurement strategies are essential not only for protecting maternal and fetal health but also for improving the quality of pharmaceutical care.
With the reform of pregnancy labeling by the U.S. Food and Drug Administration (FDA), the traditional A/B/C/D/X pregnancy risk categories have gradually been phased out and replaced by the more comprehensive Pregnancy and Lactation Labeling Rule (PLLR). Understanding this regulatory shift is increasingly important for pharmacy procurement professionals seeking to make evidence-based purchasing decisions and enhance medication safety management.
As a company specializing in global innovative medicines, specialty pharmaceuticals, and pharmaceutical supply chain services, DengYueMed continuously monitors international regulatory developments and clinical medication trends, providing hospitals, pharmacies, and pharmaceutical wholesalers with up-to-date industry insights and professional procurement guidance.
Why Did the FDA Eliminate the A/B/C/D/X Pregnancy Categories?
For decades, the FDA classified medications into five pregnancy risk categories—A, B, C, D, and X. The system was simple and easy to understand, making it widely adopted by healthcare professionals worldwide.
However, as evidence-based medicine evolved, the FDA recognized several significant limitations in this classification system.
First, medications within the same category could have substantially different risk profiles. For example, some Category C drugs showed adverse effects only in animal studies, while others lacked sufficient human clinical data. Despite sharing the same classification, their clinical implications could differ considerably.
Second, the letter-based system failed to reflect how medication risks may vary across different stages of pregnancy. Certain drugs may pose risks primarily during organogenesis in the first trimester but be relatively safer later in pregnancy. The traditional categories could not adequately communicate these distinctions.
In addition, the letter grades were often misinterpreted as representing absolute safety or danger, making individualized clinical decision-making more difficult for physicians and pharmacists.
For these reasons, the FDA officially implemented the Pregnancy and Lactation Labeling Rule (PLLR) in 2015, replacing the letter categories with more detailed, evidence-based risk descriptions.
Does the Traditional A/B/C/D/X System Still Have Value?
Although the FDA no longer uses the traditional pregnancy categories for newly approved medications, many textbooks, medical references, databases, and some countries still reference the historical classification. Therefore, pharmacy professionals should continue to understand their general meanings.
| Category | Risk Characteristics | Practical Considerations |
|---|---|---|
| A | Controlled human studies show no fetal risk | Strong safety evidence, although very few drugs qualify |
| B | Animal studies show no risk, or animal risks are not confirmed in humans | May be considered based on clinical circumstances |
| C | Animal studies suggest potential risk, while human data remain insufficient | Benefits should be carefully weighed against potential fetal risks |
| D | Positive evidence of human fetal risk exists | Use only when therapeutic benefits clearly outweigh potential risks |
| X | Proven fetal abnormalities or significant fetal risk | Contraindicated during pregnancy |
It is important to emphasize that the traditional classification should no longer serve as the sole basis for procurement or clinical decision-making.
PLLR: A More Comprehensive Risk Assessment Framework
Unlike the previous letter-based system, PLLR focuses on providing comprehensive clinical information rather than assigning a single risk category.
The updated labeling includes three major sections.
1. Pregnancy
This section summarizes known risks associated with medication use during pregnancy, including the potential for congenital malformations, miscarriage, preterm birth, or other adverse pregnancy outcomes, supported by available scientific evidence.
2. Clinical Considerations
This section provides practical guidance for healthcare professionals, including:
- Whether dosage adjustments are necessary during pregnancy;
- Which stages of pregnancy require caution or avoidance;
- Recommendations for maternal and fetal monitoring;
- The potential consequences of discontinuing therapy versus continuing treatment.
These detailed recommendations better support individualized clinical decision-making and pharmaceutical care.
3. Data
PLLR requires manufacturers to clearly identify the sources supporting the risk assessment, including animal studies, human clinical trials, post-marketing surveillance, and published case reports. This transparency enables healthcare professionals to better evaluate the strength and quality of the available evidence.
How Should Pharmacies and Procurement Professionals Adapt Their Purchasing Strategies?
As the FDA labeling system evolves, pharmaceutical procurement should transition from a category-based approach to an evidence-based approach.
1. Prioritize Current Clinical Guidelines and Prescribing Information
Procurement decisions should no longer rely solely on the historical A/B/C/D/X categories. Instead, purchasing teams should review the latest prescribing information, clinical practice guidelines, and regulatory recommendations to prioritize medications supported by robust safety evidence.
2. Optimize Inventory for Common Pregnancy-Related Healthcare Needs
Given the increasing demand for maternal healthcare products, pharmacies should consider maintaining adequate inventories of:
- Folic acid supplements and prenatal multivitamins;
- Iron and calcium supplements;
- Gastrointestinal medications commonly used during pregnancy;
- Evidence-supported antipyretic and analgesic medications appropriate for pregnant patients;
- Products for managing pregnancy-related constipation and gastroesophageal reflux.
A well-planned inventory helps improve patient access while enhancing pharmacy service quality.
3. Establish Medication Risk Alert Systems for Pregnant Patients
Pharmacies should implement internal protocols for medications with pregnancy contraindications or precautionary recommendations. During dispensing, pharmacists should proactively ask whether patients are pregnant, planning pregnancy, or breastfeeding, and provide appropriate counseling based on prescribing information and current clinical evidence.
Such proactive pharmaceutical care not only improves medication safety but also strengthens patient trust in pharmacy services.
4. Strengthen Pharmacist Education and Training
PLLR places greater emphasis on pharmacists’ ability to interpret clinical evidence rather than relying solely on simplified risk categories. Ongoing professional education should therefore include training on updated labeling requirements, international clinical guidelines, and emerging regulatory developments to support individualized medication counseling.
Why Is PLLR More Valuable Than the Traditional Classification?
Compared with the former letter-based system, PLLR offers several important advantages.
Better Individualized Risk Assessment
Instead of assigning a single letter grade, PLLR explains the available evidence, allowing healthcare professionals to evaluate risks according to each patient’s clinical situation.
Improved Clinical Decision-Making
The labeling provides practical recommendations regarding treatment continuation, monitoring requirements, and dosage considerations during pregnancy, helping clinicians make more informed decisions.
Greater Transparency
PLLR identifies the evidence supporting each recommendation, including human data, animal studies, and post-marketing safety reports, improving confidence in clinical practice.
Enhanced Pharmaceutical Care
Pharmacists can provide more comprehensive counseling by discussing both potential risks and therapeutic benefits rather than relying on simplified pregnancy categories.
Implications for Pharmaceutical Supply Chains
The transition to PLLR also has important implications for pharmaceutical procurement and inventory management.
Hospitals and pharmacies are increasingly expected to:
- Maintain evidence-based formularies;
- Update medication databases regularly;
- Train pharmacists on evolving regulatory requirements;
- Strengthen medication safety counseling;
- Support multidisciplinary medication management for pregnant patients.
As regulatory standards continue to evolve, procurement decisions increasingly emphasize clinical evidence, patient safety, and long-term healthcare outcomes rather than historical prescribing habits alone.
DengYueMed’s Perspective
As global pharmaceutical regulation continues to evolve toward greater precision and transparency, medication safety during pregnancy has become an increasingly important component of pharmaceutical services.
DengYueMed believes that pharmacy procurement should no longer focus solely on product availability. Instead, procurement decisions should integrate regulatory updates, clinical evidence, patient-centered care, and medication safety management.
By continuously monitoring FDA regulations, international treatment guidelines, and pharmaceutical innovation, healthcare institutions can optimize medication selection while providing safer pharmaceutical care for pregnant patients and other special populations.
Conclusion
The FDA’s transition from the traditional A/B/C/D/X pregnancy categories to the Pregnancy and Lactation Labeling Rule marks a significant advancement toward more precise and evidence-based medication risk assessment during pregnancy.
For pharmacies, hospitals, and pharmaceutical distributors, procurement strategies should likewise evolve from relying on simplified classification systems to comprehensive evaluations based on clinical evidence, patient needs, and current treatment guidelines.
As precision medicine and pharmaceutical care continue to advance, evidence-based medication management will become increasingly important for improving maternal and fetal safety.
As a trusted global pharmaceutical supply partner, DengYueMed remains committed to monitoring international pharmaceutical trends, sharing authoritative medication knowledge, and providing professional procurement solutions for healthcare institutions, pharmacies, and industry partners. Through continuous innovation and evidence-based supply chain management, DengYueMed strives to support safer medication use and improve healthcare outcomes for patients worldwide.